ABOS
Price
$2.53
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
137 days until earnings call
RLAY
Price
$5.81
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
98 days until earnings call
Ad is loading...

ABOS vs RLAY

Header iconABOS vs RLAY Comparison
Open Charts ABOS vs RLAYBanner chart's image
Acumen Pharmaceuticals
Price$2.53
Change-$0.00 (-0.00%)
Volume$182.3K
CapitalizationN/A
Relay Therapeutics
Price$5.81
Change-$0.00 (-0.00%)
Volume$1.39M
CapitalizationN/A
ABOS vs RLAY Comparison Chart
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RLAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ABOS vs. RLAY commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and RLAY is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (ABOS: $2.53 vs. RLAY: $5.81)
Brand notoriety: ABOS and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 97% vs. RLAY: 57%
Market capitalization -- ABOS: $152M vs. RLAY: $972.49M
ABOS [@Biotechnology] is valued at $152M. RLAY’s [@Biotechnology] market capitalization is $972.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, RLAY is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 4 TA indicator(s) are bullish while RLAY’s TA Score has 6 bullish TA indicator(s).

  • ABOS’s TA Score: 4 bullish, 6 bearish.
  • RLAY’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, RLAY is a better buy in the short-term than ABOS.

Price Growth

ABOS (@Biotechnology) experienced а -21.67% price change this week, while RLAY (@Biotechnology) price change was -7.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.83%. For the same industry, the average monthly price growth was +3.51%, and the average quarterly price growth was +6.16%.

Reported Earning Dates

ABOS is expected to report earnings on Mar 31, 2025.

RLAY is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-1.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RLAY($937M) has a higher market cap than ABOS($152M). ABOS YTD gains are higher at: -34.115 vs. RLAY (-47.230). ABOS has higher annual earnings (EBITDA): -62.11M vs. RLAY (-367.86M). RLAY has more cash in the bank: 688M vs. ABOS (260M). ABOS has less debt than RLAY: ABOS (28.2M) vs RLAY (51.1M). RLAY has higher revenues than ABOS: RLAY (35.2M) vs ABOS (0).
ABOSRLAYABOS / RLAY
Capitalization152M937M16%
EBITDA-62.11M-367.86M17%
Gain YTD-34.115-47.23072%
P/E RatioN/AN/A-
Revenue035.2M-
Total Cash260M688M38%
Total Debt28.2M51.1M55%
TECHNICAL ANALYSIS
Technical Analysis
ABOSRLAY
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RLAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYSOX91.680.02
+0.02%
Rydex S&P 500 A
ESECX33.44N/A
N/A
Eaton Vance Atlanta Capital Sel Eq C
HBLIX15.12-0.02
-0.13%
Hartford Balanced Income I
GTSVX40.35-0.49
-1.20%
Invesco Small Cap Growth R5
AIISX30.28-0.37
-1.21%
Virtus International S/C R6

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with AURA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-5.42%
AURA - ABOS
49%
Loosely correlated
-3.00%
SNDX - ABOS
49%
Loosely correlated
+2.65%
ABCL - ABOS
48%
Loosely correlated
-1.06%
INZY - ABOS
48%
Loosely correlated
-5.59%
BEAM - ABOS
47%
Loosely correlated
-1.57%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
-2.19%
XNCR - RLAY
56%
Loosely correlated
-0.42%
BCYC - RLAY
46%
Loosely correlated
-0.85%
ABOS - RLAY
45%
Loosely correlated
-5.42%
TVTX - RLAY
44%
Loosely correlated
-0.95%
VCYT - RLAY
44%
Loosely correlated
+3.37%
More